RECORDATI ORD overview

RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES + 12.1 %, EBITDA + 20.1 %. Consolidated revenues € 429.2 million, +12.1%. EBITDA (1) € 172.9 million, +20.1% Operating income € 148.4 million, +17.8%. Net income € € 111.2 million, + 20.7% Adjusted net income (2) € 125.2 million, +23.5%. Net financial position (3) : net debt of € 880.8 million; € 902.7 million at 31 December 2019. Shareholders’ equity € 1,242.9 million. Isturisa® (osilodrostat) approved in Europe...

RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018). Shareholders approve the 2019 results: consolidated revenues € 1,481.8 million (+9.6% vs 2018), EBITDA (1) € 544.0 million (+9.0%),operating income € 465,3 million (+5.2%), net income € 368,9 million (+18.1%), includes an extraordinary tax benefit of € 27.0 million from the so-called “patent box” agreed with the Italian tax authorities in December 2019. Excluding this benefit net income...

Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa ® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome Paris, 8 April, 2020 – Recordati Rare Diseases today announces the transfer of the European Marketing Authorization of Isturisa ® (osilodrostat). The transfer includes all EU member states plus the UK, Norway, Iceland and Liechtenstein. Isturisa ® is authorized for the treatment of adult patients with Cushing’s syndrome....

BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%). Consolidated revenues € 1,481.8 million, +9.6%. EBITDA (1) € 544.0 million, +9,0%. Operating income € 465.3 million, +5.2%. Net income € 368.9 million, +18.1%, includes an extraordinary tax benefit of € 27.0 million from the so-called “patent box” agreed with the Italian tax authorities in December 2019. Excluding this benefit net income would have...

Recordati: Isturisa® (Osilodrostat) Approved In The U.S. Recordati Announces US NDA Approval of Isturisa® (osilodrostat), the First and Only FDA Approved Cortisol Synthesis Inhibitor for Patients with Cushing's Disease. Company Builds Endocrinology Business Unit in the U.S. PR Newswire MILAN, March 9, 2020 MILAN , March 9, 2020 /PRNewswire/ -- Recordati today announces the FDA approval of Isturisa ® (osilodrostat) for the treatment of patients with Cushing's disease for whom pituitary surgery...

RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%. Consolidated revenues € 1,481.8 million, +9.6%. EBITDA (1) € 544.0 million, +9,0%. Operating income € 465.3 million, +5.2%. Net income € 368.8 million, +18.1%, includes an extraordinary tax benefit of € 27.0 million from the so-called “patent box” agreed with the Italian tax authorities in December 2019. Excluding this benefit net income would have been € 341.9 million,...

RECORDATI: ISTURISA ® (OSILODROSTAT) APPROVED Milan, 15 January, 2020 – Recordati announces that the European Commission has granted marketing authorisation for the orphan medicinal product Isturisa ® (osilodrostat), indicated for the treatment of endogenous Cushing’s syndrome (CS) in adults. The active substance of Isturisa® is osilodrostat, a cortisol synthesis inhibitor. Osilodrostat works by inhibiting 11-beta-hydroxylase, an enzyme responsible for the final step of cortisol...

RECORDATI: CHMP ADOPTS POSITIVE OPINION FOR ISTURISA ® (OSILODROSTAT) Milan, 15 November 2019 – Recordati announces that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Isturisa®, indicated for the treatment of endogenous Cushing’s syndrome in adults. The benefits with Isturisa® are its ability to control or normalise raised cortisol levels. The active substance of...

RECORDATI ANNOUNCES GROWTH IN THE FIRST NINE MONTHS 2019. REVENUES +8.6%, EBITDA +7.8%, OPERATING INCOME +4.9%, NET INCOME +6.6%. INTERIM DIVIDEND € 0.48 (+6.7%). Consolidated revenues € 1,100.4 million, +8.6%. EBITDA (1) € 409.6 million, +7.8% Operating income € 353.5 million, +4.9%. Net income € 253.7 million, +6.6%. Net financial position (2) : net debt of € 498.7 million. Shareholders’ equity € 1,179.6 million. Interim 2019 dividend of € 0.48 per share to be distributed....

RECORDATI: ACQUISITION OF WORLDWIDE RIGHTS TO SIGNIFOR® AND OSILODROSTAT (LCI699) COMPLETED Milan, 23 October 2019 – Recordati announced the successful completion of the acquisition from Novartis of worldwide rights to Signifor® and Signifor® LAR® for the treatment of Cushing’s disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed, following the agreement signed on 12 July 2019. The acquisition also covers the worldwide rights to...

Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland , Puteaux, France, October 9, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces it will be co-hosting alongside Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, part of Recordati Group, a satellite symposium at the...

Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological Research Annual Meeting 2019 Lugano-Switzerland , Puteaux-France, September 19 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs and part of Recordati Group, today announce...

RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY Milan, 15 April 2019 – Recordati S.p.A. will be hosting a meeting with the financial community on: Thursday 9 May at 10:30 am GMT (Registration at 9:30 am GMT) London Stock Exchange 10 Paternoster Square, London Recordati’s first quarter 2019 results and the Group’s development strategy and objectives for the period 2019-2021 will be presented at this meeting. The meeting will be held in English. Anyone wishing to attend must register by...

RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%). Consolidated revenues € 1,352.2 million, +5.0%. EBITDA (1) € 499.1 million, +9.8% Operating income € 442.2 million, +8.8%. Net income € 312.4 million, +8.2%. Net financial position (2) : net debt of € 588.4 million. Dividend for 2018 € 0.92 per share, of...